The RAS‐related GTPase RHOB confers resistance to EGFR‐tyrosine kinase inhibitors in non‐small‐cell lung cancer via an AKT‐dependent mechanism

The RAS‐related GTPase RHOB confers resistance to EGFR‐tyrosine kinase inhibitors in non‐small‐cell lung cancer via an AKT‐dependent mechanism

Abstract Although lung cancer patients harboring EGFR mutations benefit from treatment with EGFR‐tyrosine kinase inhibitors (EGFR‐TKI), most of them rapidly relapse. RHOB GTPase is a critical player in both lung carcinogenesis and the EGFR signaling pathway; therefore, we hypothesized that it could...

Full description

Saved in:
Bibliographic Details
Main Authors: Olivier Calvayrac, Julien Mazières, Sarah Figarol, Claire Marty‐Detraves, Isabelle Raymond‐Letron, Emilie Bousquet, Magali Farella, Estelle Clermont‐Taranchon, Julie Milia, Isabelle Rouquette, Nicolas Guibert, Amélie Lusque, Jacques Cadranel, Nathalie Mathiot, Ariel Savina, Anne Pradines, Gilles Favre
Format: Article
Language:English
Published: Springer Nature 2016-12-01
Series:EMBO Molecular Medicine
Subjects:
RhoB
EGFR
TKI
AKT
resistance
Online Access:https://doi.org/10.15252/emmm.201606646
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.15252/emmm.201606646

Similar Items